Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

404

Not found

This newslink doesn't exist or it was removed.

Go to Homempage.

Sugerencias de la Hemeroteca

Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal

CNBC USA Health March 21, 2023

thumbnailIn this articleCarl IcahnAdam Jeffery CNBC Biotech company pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees do not add value. The San Diego-based DNA... + más

Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC

Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC


FTC orders Illumina to unwind $7B deal for cancer test developer Grail

Fox Business USA Business April 03, 2023

thumbnailCheck out whats clicking on FoxBusiness.com The on Monday ordered life sciences company Illumina to unwind its $7.1 billion acquisition of cancer detection test developer Grail Inc., citing antitrust concerns. The commission voted unanimously in a 4-0 decision to force Illumina... + más

Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC

F.T.C. Orders Gene-Sequencing Company Illumina to Divest Acquisition | The New York Times


F.T.C. Orders Gene-Sequencing Company Illumina to Divest Acquisition

The New York Times USA Business April 03, 2023

thumbnailThe Federal Trade Commission on Monday ordered Illumina, the leading maker of gene-sequencing machines, to divest Grail, a cancer-test developer.The move by the F.T.C. is the latest development in a case seen by antitrust experts as a to stop big companies from buying fledgling... + más

FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business

Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC


EU fines US firm Illumina $475 million for jumping gun on buying cancer-screening company Grail

WPLG Local 10 USA Tech July 12, 2023

thumbnailBRUSSELS – The European Union on Wednesday slapped a $475 million fine on U.S. biotech giant Illumina for buying cancer-screening company Grail without regulators' approval, the latest setback for the deal.Illumina announced an $7.1 billion acquisition of Grail in 2020,... + más

Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC

FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business


EU orders biotech giant Illumina to unwind $7.1 billion purchase of cancer-screening company Grail

ABC News USA Health October 12, 2023

thumbnailBRUSSELS -- The European Union on Thursday ordered U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators in the 27-nation bloc.The EU already slapped a $475 million fine on... + más

Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC

FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business



About iurex | Privacy Policy | Disclaimer |